DNA-Based Synthetic Growth Factor Surrogates with Fine-Tuned Agonism

2019 ◽  
Author(s):  
Ryosuke Ueki ◽  
Momoko Akiyama ◽  
Shinsuke Sando
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Receptor Agonist ◽  
Dna Aptamer ◽  
Cytokine Receptors ◽  
Great Promise ◽  
High Demand ◽  
Synthetic Receptor ◽  
Signal Activity ◽  
Synthetic Growth

Designing synthetic surrogates of functional proteins is an important, albeit challenging, task in the field of chemistry. A strategy toward the design of synthetic agonists for growth factors or cytokine receptors that elicit a desired signal activity has been in high demand, as such ligands hold great promise as safer and more effective therapeutics. In the present study, we used a DNA aptamer as a building block and described the strategy-guided design of a synthetic receptor agonist with fine-tuned agonism.

DNA-Based Synthetic Growth Factor Surrogates with Fine-Tuned Agonism

2019 ◽  
Author(s):  
Ryosuke Ueki ◽  
Momoko Akiyama ◽  
Shinsuke Sando
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Receptor Agonist ◽  
Dna Aptamer ◽  
Cytokine Receptors ◽  
Great Promise ◽  
High Demand ◽  
Synthetic Receptor ◽  
Signal Activity ◽  
Synthetic Growth

Designing synthetic surrogates of functional proteins is an important, albeit challenging, task in the field of chemistry. A strategy toward the design of synthetic agonists for growth factors or cytokine receptors that elicit a desired signal activity has been in high demand, as such ligands hold great promise as safer and more effective therapeutics. In the present study, we used a DNA aptamer as a building block and described the strategy-guided design of a synthetic receptor agonist with fine-tuned agonism.

scholarly journals DNA Aptamer Assembly as a Vascular Endothelial Growth Factor Receptor Agonist

2015 ◽  
Vol 25 (5) ◽  
pp. 227-234 ◽  
Author(s):  
Vidhya Ramaswamy ◽  
Adam Monsalve ◽  
Larysa Sautina ◽  
Mark S. Segal ◽  
Jon Dobson ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Receptor Agonist ◽  
Growth Factor Receptor ◽  
Dna Aptamer ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Insulin and epidermal growth factor are growth factors for isolated porcine thyroid follicles

1985 ◽  
Vol 110 (1_Suppla) ◽  
pp. S74
Author(s):  
R. GÄRTNER ◽  
W. GREIL ◽  
R. DEMHARTER ◽  
K. HORN
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Epidermal Growth

scholarly journals Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems

2021 ◽  
pp. 1-7
Author(s):  
Sarah Jarrin ◽  
Abrar Hakami ◽  
Ben Newland ◽  
Eilís Dowd
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Growth Factors ◽  
Growth Factor ◽  
Ex Vivo ◽  
Brain Regions ◽  
Delivery Systems ◽  
Alternative Delivery

Despite decades of research and billions in global investment, there remains no preventative or curative treatment for any neurodegenerative condition, including Parkinson’s disease (PD). Arguably, the most promising approach for neuroprotection and neurorestoration in PD is using growth factors which can promote the growth and survival of degenerating neurons. However, although neurotrophin therapy may seem like the ideal approach for neurodegenerative disease, the use of growth factors as drugs presents major challenges because of their protein structure which creates serious hurdles related to accessing the brain and specific targeting of affected brain regions. To address these challenges, several different delivery systems have been developed, and two major approaches—direct infusion of the growth factor protein into the target brain region and in vivo gene therapy—have progressed to clinical trials in patients with PD. In addition to these clinically evaluated approaches, a range of other delivery methods are in various degrees of development, each with their own unique potential. This review will give a short overview of some of these alternative delivery systems, with a focus on ex vivo gene therapy and biomaterial-aided protein and gene delivery, and will provide some perspectives on their potential for clinical development and translation.

scholarly journals Growth factors in the regulation of reparative response in the presence of peritoneal damage

2020 ◽  
Vol 5 (4) ◽  
Author(s):  
Irina A. Shurygina ◽  
Мichael G. Shurygin ◽  
Lubov V. Rodionova ◽  
Nataliya I. Ayushinova
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Extended Period ◽  
Tissue Growth ◽  
Tissue Response ◽  
Heparin Binding ◽  
Lower Quadrant ◽  
Male Wistar Rats ◽  
The Right ◽  
Endothelial Growth Factor

AbstractObjectivesTo study the expression of growth factors in the regulation of tissue repair after peritoneal damage tissue response to peritoneal damage.MethodsExperimental study in 35 male Wistar rats determining the evolution over time of the tissue response to aseptic peritoneal damage. A standardized bowel and peritoneal lesions were created in the right lower quadrant by laparotomy. Then, tissular expression of growth factors was evaluated by multiplex polymerase chain reaction at seven timepoints between 6 h and 30 days, postoperatively.ResultsTissular responses of granulocyte-stimulating factors (Csf2, Csf3), connective tissue growth factor (Ctgf), epidermal growth factors and receptor (Egf, Egfr), fibroblast growth factors (Fgf2, 7 and 10), heparin binding EGF-like growth factor (Hbegf), hepatocyte growth factor (Hgf), insulin-like growth factor-1 (Igf1), mitogenic transforming growth factors (Tgfa, Tgfb1, Tgfbr3), and vascular endothelial growth factor A (Vegfa) were biphasic with a first expression peak at day 3, followed by a more pronounced peak at day 14.ConclusionsWe observed a long-lasting, widespread response of tissular growth factors for at least two weeks after peritoneal damage. To be clinically effective, the prophylaxis of postoperative adhesions might be needed for an extended period of time.

scholarly journals Utilizing the ABC Transporter for Growth Factor Production by fleQ Deletion Mutant of Pseudomonas fluorescens

Biomedicines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 679
Author(s):  
Benedict-Uy Fabia ◽  
Joshua Bingwa ◽  
Jiyeon Park ◽  
Nguyen-Mihn Hieu ◽  
Jung-Hoon Ahn
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Pseudomonas Fluorescens ◽  
Abc Transporter ◽  
Transforming Growth Factor Beta ◽  
Deletion Mutant ◽  
Transforming Growth Factor ◽  
Gene Knockout ◽  
Type I ◽  
Double Deletion

Pseudomonas fluorescens, a gram-negative bacterium, has been proven to be a capable protein manufacturing factory (PMF). Utilizing its ATP-binding cassette (ABC) transporter, a type I secretion system, P. fluorescens has successfully produced recombinant proteins. However, besides the target proteins, P. fluorescens also secretes unnecessary background proteins that complicate protein purification and other downstream processes. One of the background proteins produced in large amounts is FliC, a flagellin protein. In this study, the master regulator of flagella gene expression, fleQ, was deleted from P. fluorescens Δtp, a lipase and protease double-deletion mutant, via targeted gene knockout. FleQ directs flagella synthesis, so the new strain, P. fluorescens ΔfleQ, does not produce flagella-related proteins. This not only simplifies purification but also makes P. fluorescens ΔfleQ an eco-friendly expression host because it will not survive outside a controlled environment. Six recombinant growth factors, namely, insulin-like growth factors I and II, beta-nerve growth factor, fibroblast growth factor 1, transforming growth factor beta, and tumor necrosis factor beta, prepared using our supercharging method, were successfully secreted by P. fluorescens ΔfleQ. Our findings demonstrate the potential of P. fluorescens ΔfleQ, combined with our supercharging process, as a PMF.

DNA‐based Synthetic Growth Factor Surrogates with Fine‐tuned Agonism

2021 ◽  
Author(s):  
Momoko Akiyama ◽  
Ryosuke Ueki ◽  
Masataka Yanagawa ◽  
Mitsuhiro Abe ◽  
Michio Hiroshima ◽  
...  
Keyword(s):  
Growth Factor ◽  
Synthetic Growth

scholarly journals Antiproliferative function of glia maturation factor beta.

1990 ◽  
Vol 1 (10) ◽  
pp. 741-746 ◽  
Author(s):  
R Lim ◽  
W X Zhong ◽  
A Zaheer
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Target Cell ◽  
G1 Phase ◽  
Glia Maturation Factor ◽  
Pituitary Extract ◽  
Mitogenic Effect ◽  
Maturation Factor ◽  
Cultured Astrocytes

Recombinant human glia maturation factor beta (GMF-beta) reversibly inhibits the proliferation of neoplastic cells in culture by arresting the cells in the G0/G1 phase. This phenomenon is not target-cell specific, as neural and nonneural cells are equally inhibited. When tested simultaneously, GMF-beta suppresses the mitogenic effect of acidic fibroblasts growth factor (aFGF), but the two are synergistic in promoting the morphologic differentiation of cultured astrocytes. GMF-beta also counteracts the growth-stimulating effect of pituitary extract and cholera toxin on Schwann cells. The results underscore the regulatory role of GMF-beta and its intricate interaction with the mitogenic growth factors.

Sign in / Sign up

Export Citation Format

Share Document